AVTE Stock Price, Aerovate Therapeutics, . Quote, Chart

Market Summary

USD21.77+0.20

Market Closed

0.93%

AVTE Alerts

6 major insider sales recently.

AVTE Stock Price

View Fullscreen

AVTE RSI Chart

AVTE Valuation

Market Cap

606.6M

Price/Earnings (Trailing)

-8.03

EV/EBITDA

-7.74

Price/Free Cashflow

-10.66

MarketCap/EBT

-8.04

AVTE Price/Earnings (Trailing)

AVTE Profitability

Return on Equity

-69%

Return on Assets

-59.27%

Free Cashflow Yield

-9.38%

AVTE Fundamentals

AVTE Earnings

Earnings (TTM)

-75.5M

Earnings Growth (Yr)

-35.89%

Earnings Growth (Qtr)

-4.34%

Breaking Down AVTE Revenue

Last 7 days

-1.3%

Last 30 days

-23.6%

Last 90 days

23.1%

Trailing 12 Months

2.4%

How does AVTE drawdown profile look like?

AVTE Financial Health

Current Ratio

7.04

AVTE Investor Care

Shares Dilution (1Y)

12.27%

Diluted EPS (TTM)

-2.88

Tracking the Latest Insider Buys and Sells of Aerovate Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 17, 2024	gillies hunter	sold	-89,521	22.3805	-4,000	chief medical officer
Apr 17, 2024	dake benjamin t	acquired	14,665	2.14	6,853	see remarks
Apr 17, 2024	dake benjamin t	sold	-153,327	22.3737	-6,853	see remarks
Apr 17, 2024	gillies hunter	acquired	6,960	1.74	4,000	chief medical officer
Apr 16, 2024	noyes timothy p	sold	-246,971	24.6971	-10,000	chief executive officer
Apr 16, 2024	noyes timothy p	acquired	21,400	2.14	10,000	chief executive officer
Apr 10, 2024	eldridge george a	acquired	16,050	2.14	7,500	see remarks
Apr 10, 2024	eldridge george a	sold	-201,392	26.8522	-7,500	see remarks
Apr 09, 2024	grayzel david s.	sold	-334,478	28.15	-11,882	-
Apr 01, 2024	eldridge george a	sold	-390,208	31.2291	-12,495	see remarks

Which funds bought or sold AVTE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-24.33	-9,283	818,025	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-75.77	-22,000	10,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	47,366	118,310	-%
Apr 11, 2024	Fortitude Family Office, LLC	unchanged	-	2,887	12,301	0.01%
Apr 05, 2024	GAMMA Investing LLC	added	17.5	1,235	2,780	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	4.63	6,055,370	14,185,200	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.41	50,025	125,732	-%
Feb 20, 2024	EVENTIDE ASSET MANAGEMENT, LLC	new	-	275,588	275,588	-%
Feb 15, 2024	BARCLAYS PLC	added	300	296,000	348,000	-%

Are Funds Buying or Selling AVTE?

Are funds buying AVTE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AVTE

No. of Funds

AVTE Alerts

6 major insider sales recently.

Unveiling Aerovate Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 20, 2024	sofinnova venture partners x, l.p.	13.6%	3,758,686	SC 13D/A
Feb 14, 2024	baker bros. advisors lp	6.1%	1,680,517	SC 13G/A
Feb 14, 2024	citadel advisors llc	0.0%	6	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	0.00%	0	SC 13G/A
Feb 09, 2024	tcg crossover gp i, llc	8.0%	2,201,274	SC 13G
Jun 27, 2023	ra capital management, l.p.	30%	8,293,148	SC 13D/A
Feb 14, 2023	baker bros. advisors lp	8.0%	1,976,868	SC 13G/A
Feb 14, 2023	citadel advisors llc	6.4%	6	SC 13G/A
Feb 14, 2023	cormorant asset management, lp	3.03%	745,436	SC 13G/A
Feb 06, 2023	sofinnova venture partners x, l.p.	15.3%	3,758,686	SC 13D/A

Recent SEC filings of Aerovate Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 19, 2024	4	Insider Trading
Apr 19, 2024	4	Insider Trading
Apr 18, 2024	4	Insider Trading
Apr 17, 2024	144	Notice of Insider Sale Intent
Apr 17, 2024	144	Notice of Insider Sale Intent
Apr 16, 2024	144	Notice of Insider Sale Intent
Apr 12, 2024	4	Insider Trading

Peers (Alternatives to Aerovate Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Aerovate Therapeutics, Inc. News

Latest updates

Aerovate Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-9.6%	127	141	156	124	135	148	156	167	175	184	62.00	-
Current Assets	-9.7%	124	138	152	121	131	145	153	166	174	183	59.00	5.00
Cash Equivalents	-27.0%	23.00	32.00	61.00	27.00	22.00	22.00	27.00	28.00	54.00	181	59.00	5.00
Net PPE	-8.9%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	18.5%	18.00	15.00	14.00	11.00	9.00	9.00	5.00	5.00	3.00	4.00	-	2.00
Current Liabilities	19.8%	18.00	15.00	13.00	11.00	8.00	8.00	4.00	5.00	3.00	4.00	4.00	2.00
Shareholder's Equity	-12.9%	109	126	142	113	127	139	151	162	172	180	-	-
Retained Earnings	-14.3%	-163	-143	-123	-104	-87.90	-72.88	-59.29	-47.30	-36.39	-28.17	-21.98	-13.41
Additional Paid-In Capital	1.4%	273	269	266	218	215	213	211	210	209	208	0.00	0.00
Shares Outstanding	0.4%	28.00	28.00	28.00	25.00	25.00	24.00	24.00	24.00	24.00	8.00	-	0.00
Float	-	-	-	232	-	-	-	157	-	-	-	185	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	5.2%	-14,800	-15,611	-14,943	-11,424	-14,865	-9,720	-8,876	-5,661	-13,093	-6,526	-4,005	-3,775	-	-	-
Share Based Compensation	0.4%	3,251	3,237	3,034	2,384	1,729	1,499	1,224	1,024	854	845	321	23.00	-	-	-
Cashflow From Investing	143.0%	5,648	-13,130	3,983	15,375	14,486	4,645	8,194	-20,399	-113,338	-56.00	-	-40.00	-	-	-
Cashflow From Financing	2215.0%	463	20.00	45,290	223	357	37.00	-	-	-250	128,310	54,514	7,883	-	-	-

AVTE Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 64,219	$ 38,622
General and administrative	17,190	14,615
Total operating expenses	81,409	53,237
Loss from operations	(81,409)	(53,237)
Other income (expense):
Interest income	5,945	1,830
Other expense:	(1)	(79)
Total other income	5,944	1,751
Net loss before income taxes	(75,465)	(51,486)
Provision for income taxes	56	25
Net loss	(75,521)	(51,511)
Comprehensive loss:
Net loss	(75,521)	(51,511)
Other comprehensive loss:
Unrealized gain (loss) on securities	703	(407)
Comprehensive loss	$ (74,818)	$ (51,918)
Net loss per share, basic	$ (2.87)	$ (2.10)
Net loss per share, diluted	$ (2.87)	$ (2.10)
Weighted-average shares of common stock outstanding, basic	26,331,630	24,472,104
Weighted-average shares of common stock outstanding, diluted	26,331,630	24,472,104

AVTE Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 23,491	$ 22,397
Short-term investments	98,948	106,823
Prepaid expenses and other current assets	1,793	2,276
Total current assets	124,232	131,496
Property and equipment, net	288	242
Operating lease right-of-use assets	614	1,003
Other long-term assets	2,284	2,560
Total assets	127,418	135,301
Current liabilities:
Accounts payable	2,396	2,575
Accrued and other current liabilities	14,821	4,822
Operating lease liabilities	420	385
Total current liabilities	17,637	7,782
Operating lease liabilities, net of current portion	255	705
Other liabilities	70	71
Total liabilities	17,962	8,558
Commitments and contingencies (Note 5)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; no shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively
Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 27,762,703 and 24,722,974 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	3	2
Additional paid-in capital	272,640	215,110
Accumulated other comprehensive income (loss)	237	(466)
Accumulated deficit	(163,424)	(87,903)
Total stockholders' equity	109,456	126,743
Total liabilities and stockholders' equity	$ 127,418	$ 135,301

About Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Timothy P. Noyes M.B.A.
WEBSITE	https://aerovatetx.com
INDUSTRY	Biotechnology
EMPLOYEES	43

Aerovate Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Aerovate Therapeutics, Inc.? What does AVTE stand for in stocks?

AVTE is the stock ticker symbol of Aerovate Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aerovate Therapeutics, Inc. (AVTE)?

As of Fri Apr 26 2024, market cap of Aerovate Therapeutics, Inc. is 606.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVTE stock?

You can check AVTE's fair value in chart for subscribers.

What is the fair value of AVTE stock?

You can check AVTE's fair value in chart for subscribers. The fair value of Aerovate Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aerovate Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVTE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aerovate Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether AVTE is over valued or under valued. Whether Aerovate Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Aerovate Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVTE.